Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice
- 15 May 1984
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 33 (5) , 683-687
- https://doi.org/10.1002/ijc.2910330520
Abstract
Intraperitoneal (i.p.) injection of substances that can ignite the alternative pathway of complement, namely isolated human C3b or C3(H2O), guinea-pig C3(H2O) or cobra venom factor, or conventionally prepared zymosan, will reproducibly and very significantly increase the mean survival time of C57BL mice previously inoculated i.p. with melanoma cells. The effect is greater at higher doses and earlier post-inoculation (p.i.) administration, but the substances are active at low doses (30–100 μg/mouse) if given early enough. It is likely that C3b or C3(H2O) was the previously unidentified anti-tumour factor activated in serum by S. aureus treatment or serum fractionation and described elsewhere. Activation of the alternative pathway of complement appears to have potential interest for cancer therapy.This publication has 22 references indexed in Scilit:
- Protein a treatment of cancer: Activation of a serum component with trans‐species anti‐B16 melanoma activityInternational Journal of Cancer, 1983
- Extracorporeal immunoadsorption of plasma from a metastatic colon carcinoma patient by protein a-containing nonviable staphylococcus aureus. Clinical, biochemical, serologic, and histologic evaluation of the Patient's responseCancer, 1982
- The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serumBiochemical Journal, 1981
- The separation of functionally distinct forms of the third component of human complement (C3)Biochemical Journal, 1981
- [11] Preparation of human factor of the alternative pathway of complementPublished by Elsevier ,1981
- A simple new method of measuring the capacity to activate the alternative complement pathwayImmunology Letters, 1980
- Efficient removal of abnormal immunoglobulin G from the plasma of a multiple myeloma patient description of a new method for treatment of the hyperviscosity syndrome. Description of a new method for treatment of the hyperviscosity syndromeCancer, 1980
- Molecular Biology and Chemistry of the Alternative Pathway of ComplementPublished by Elsevier ,1980
- ComplementPublished by Elsevier ,1979
- Complement and Leukocyte-Mediated Pulmonary Dysfunction in HemodialysisNew England Journal of Medicine, 1977